Skip to content

A prospective randomised controlled study to evaluate the efficacy and safety of Q-switched NdYag Laser in the treatment of Lichen Planus Pigmentosus

Efficacy and safety of Q-switched NdYag Laser in the treatment of Lichen Planus Pigmentosus - NIL

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/04/109090
Enrollment
80
Registered
2026-04-22
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L819- Disorder of pigmentation, unspecified

Interventions

Intervention1: Q-Switched Nd:YAG Laser (1064 nm): Q-Switched Nd:YAG laser (1064 nm) will be administered to patients with Lichen Planus Pigmentosus at 4 weekly intervals for a total of 6 sessions. Tre

Sponsors

Dr Abhijeet Kumar Jha
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adult male and female patients aged 18 60 years with a clinical diagnosis of Lichen Planus Pigmentosus attending the dermatology outpatient department will be enrolled. Participants must be willing to provide written informed consent and comply with study procedures and follow-up visits. Patients with pregnancy or lactation, history of keloidal tendency, active cutaneous infection at the treatment site, recent treatment for Lichen Planus Pigmentosus within the last 3 months, or known photosensitivity disorders will be excluded from the study.

Exclusion criteria

Exclusion criteria: atients with pregnancy or lactation, history of keloidal tendency, active cutaneous infection at the treatment site, recent treatment for Lichen Planus Pigmentosus within the last 3 months, or known photosensitivity disorders will be excluded from the study.

Design outcomes

Primary

MeasureTime frame
Dermoscopy Change in L value by SpectrophotometerTimepoint: 4,8,12,16,20, 24 weeks

Secondary

MeasureTime frame
physician global assessment (PGA), Acquired dermal macular hyperpigmentation scoring (ADMH)Timepoint: 4,8,12,16,20, 24 weeks

Countries

India

Contacts

Public ContactAbhijeet Kumar Jha

Patna Medical College

drabhijeetjha@gmail.com09631444797

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026